538 related articles for article (PubMed ID: 20601076)
1. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
[TBL] [Abstract][Full Text] [Related]
3. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
[TBL] [Abstract][Full Text] [Related]
4. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
[TBL] [Abstract][Full Text] [Related]
5. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.
Costa LE; Chávez-Fumagalli MA; Martins VT; Duarte MC; Lage DP; Lima MI; Pereira NC; Soto M; Tavares CA; Goulart LR; Coelho EA
Parasitology; 2015 Sep; 142(10):1335-47. PubMed ID: 26099574
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
8. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.
Grenfell RF; Marques-da-Silva EA; Souza-Testasicca MC; Coelho EA; Fernandes AP; Afonso LC; Rezende SA
Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):818-22. PubMed ID: 20944999
[TBL] [Abstract][Full Text] [Related]
9. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.
Lage DP; Martins VT; Duarte MC; Garde E; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Parasite Immunol; 2015 Dec; 37(12):646-56. PubMed ID: 26457798
[TBL] [Abstract][Full Text] [Related]
12. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40(-/-) C57BL/6 mice.
Hernández Sanabria MX; Afonso LC; Golgher D; Tafuri WL; Vieira LQ
Microbes Infect; 2007 Jul; 9(9):1124-34. PubMed ID: 17662634
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with a CD4
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
[TBL] [Abstract][Full Text] [Related]
15. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
17. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
[TBL] [Abstract][Full Text] [Related]
18. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
[TBL] [Abstract][Full Text] [Related]
19. Protein-energy malnutrition decreases immune response to Leishmania chagasi vaccine in BALB/c mice.
Malafaia G; Serafim TD; Silva ME; Pedrosa ML; Rezende SA
Parasite Immunol; 2009 Jan; 31(1):41-9. PubMed ID: 19121082
[TBL] [Abstract][Full Text] [Related]
20. A recombinant chimeric protein composed of human and mice-specific CD4
Martins VT; Duarte MC; Lage DP; Costa LE; Carvalho AM; Mendes TA; Roatt BM; Menezes-Souza D; Soto M; Coelho EA
Parasite Immunol; 2017 Jan; 39(1):. PubMed ID: 27593711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
